RESUMO
A transdermal patch formulation of a non-steroidal anti-inflammatory drug (NSAID) used by a 44-year-old man resulted in acute interstitial nephritis and acute tubular injury. This patient also had a history of mild kidney dysfunction and osteoporosis. The NSAID patch had been prescribed after a traffic accident. He was also receiving a vitamin D analog and taking over-the-counter calcium supplements. Two months later, renal dysfunction and hypercalcemia were discovered. A renal biopsy showed acute interstitial nephritis and acute tubular injury. Once these agents were withdrawn, the renal function recovered. This is the first reported occurrence of biopsy-proven acute interstitial nephritis attributable to NSAID patch usage.
Assuntos
Injúria Renal Aguda/induzido quimicamente , Injúria Renal Aguda/fisiopatologia , Anti-Inflamatórios não Esteroides/efeitos adversos , Nefropatias/tratamento farmacológico , Nefrite Intersticial/induzido quimicamente , Nefrite Intersticial/fisiopatologia , Fenilpropionatos/efeitos adversos , Adesivo Transdérmico/efeitos adversos , Adulto , Humanos , Japão , MasculinoRESUMO
BACKGROUND: Melasma is an acquired disorder of hyperpigmentation that is often recalcitrant to current therapies. Microneedling is used to treat scars, striae, and rhytides and has a relatively low risk of post-treatment dyspigmentation. Several studies have examined its use in melasma. OBJECTIVE: To review the published evidence on the efficacy and safety of microneedling in the treatment of melasma. METHODS: A systematic review was performed. A meta-analysis could not be performed because of methodological differences across studies and data heterogeneity. RESULTS: Eight studies were included for analysis. Most studies assessed the utility of microneedling in combination with other topical therapies and detected some success. However, microneedling-mediated transdermal delivery of medications is not superior to microinjections of medications. There is less evidence supporting the use of microneedling as monotherapy. Microneedling, when used with a 1064-nm Q-switched Nd:YAG laser, may provide additional benefit, although with a risk of post-treatment dyspigmentation. CONCLUSION: Based on low-quality evidence, microneedling may play a role in the treatment of melasma, with the mechanism of action likely being the facilitation of delivery of topical therapies to the epidermis and dermis, and one ancillary benefit of this approach being the very low risk of postinflammatory hyperpigmentation.
Assuntos
Fármacos Dermatológicos/administração & dosagem , Agulhamento Seco/métodos , Melanose/terapia , Administração Cutânea , Terapia Combinada/efeitos adversos , Terapia Combinada/instrumentação , Terapia Combinada/métodos , Fármacos Dermatológicos/efeitos adversos , Agulhamento Seco/efeitos adversos , Agulhamento Seco/instrumentação , Humanos , Microinjeções/efeitos adversos , Microinjeções/métodos , Agulhas/efeitos adversos , Adesivo Transdérmico/efeitos adversos , Resultado do TratamentoRESUMO
Objective: To investigate the safety and efficacy of the Weitan Waifu patch on the postsurgical gastroparesis syndrome (PGS) of gastrointestinal cancer. Methods: The multi-center, double-blind, randomized controlled trial was conducted with superiority design. Patients with PGS of gastrointestinal cancer diagnosed in 4 AAA hospitals and the abdominal symptom manifested as cold syndrome by Chinese local syndrome differentiation were recruited. These patients were randomly divided into two groups according to 1â¶1 proportion. Placebo or Weitan Waifu patch was applied in control group or intervention group, respectively, based on the basic treatments, including nutrition support, gastrointestinal decompression, promoting gastric dynamics medicine.Two acupuncture points (Zhongwan and Shenque) were stuck with placebo in control group or patch in treatment group. The intervention course was 14 days or reached the effective standard. Results: From July 15, 2013 to Jun 3, 2015, 128 participants were recruited and 120 eligible cases were included in the full analysis set (FAS), and 60 cases in each group. 88 cases were included in the per-protocol set (PPS), including 45 cases in the treatment group and 43 cases in the control group. In the FAS, the clinical effective rate in the treatment group was 68.3%, significantly superior than 41.7% of the control group (P=0.003). The medium time of effective therapy in the treatment group was 8 days, significantly shorter than 10 days in the control group (P=0.017). In the FAS, 3 adverse events occurred in the treatment group, including mild to moderate decrustation, pruritus and nausea. The incidence rate of adverse events was 5.0% (3/60) and these symptoms were spontaneously remitted after drug withdrawal. No severe adverse events were observed in the control group. There was no significant difference between these two groups (P=0.244). Conclusion: Weitan Waifu patch is a safely and effectively therapeutic method for patients with PGS (cold syndrome) of gastroenterological cancer. Trial registration: International Standard Randomized Controlled Trial Number Register, ISRCTN18291857.
Assuntos
Medicamentos de Ervas Chinesas/uso terapêutico , Neoplasias Gastrointestinais/cirurgia , Gastroparesia/tratamento farmacológico , Complicações Pós-Operatórias/tratamento farmacológico , Adesivo Transdérmico , Pontos de Acupuntura , Método Duplo-Cego , Humanos , Síndrome , Adesivo Transdérmico/efeitos adversos , Resultado do TratamentoRESUMO
OBJECTIVES: To investigate the long-term safety and tolerability of capsaicin 8% patch repeat treatment in nondiabetic patients with peripheral neuropathic pain. METHODS: A prospective, open-label, observational study in patients with postherpetic neuralgia, posttraumatic or postsurgical nerve injury, HIV-associated distal sensory polyneuropathy, or other peripheral neuropathic pain, and average daily pain score ≥4, who received ≤6 capsaicin 8% patch treatments over 52 weeks according to clinical need (retreatment at 9 to 12 wk intervals). Sensory testing and analgesic effectiveness were assessed using "bedside tests" and Brief Pain Inventory (question 5). RESULTS: Overall, 306 patients received treatment. Treatment-emergent adverse events (TEAEs) and drug-related TEAEs were reported by 252 (82.4%) and 207 (67.6%) patients. Application site pain was the most common drug-related TEAE (n=112, 36.6%); no drug-related serious TEAEs were reported. Sensory category shift analyses from baseline to end of study (EoS) in patients attending at least 2 sensory visits (n=278 for all tests except warm, n=277) found sensory deterioration/loss in at least 1 modality in 50.4% (n=140); deterioration/loss in 1, 2, 3, 4, or 5 modalities occurred in 26.6% (n=74), 14.0% (n=39), 5.8% (n=16), 2.5% (n=7), and 1.4% (n=4) cases. Newly emergent hyperesthesia or allodynia was apparent in 1.1% to 3.6% of the cases (depending on modality) by EoS. Between 25.2% and 32.0% of patients reported improvement in a sensory modality by EoS. Average daily pain was 6.6 and 4.7 at baseline and month 12. CONCLUSIONS: Generally, capsaicin 8% patch repeat treatment over 52 weeks was well tolerated, with variable alteration in sensory function and minimal chance of complete sensory loss.
Assuntos
Analgésicos não Narcóticos/administração & dosagem , Capsaicina/administração & dosagem , Neuralgia/tratamento farmacológico , Idoso , Analgésicos não Narcóticos/efeitos adversos , Capsaicina/efeitos adversos , Feminino , Humanos , Hiperalgesia/tratamento farmacológico , Hiperalgesia/fisiopatologia , Masculino , Pessoa de Meia-Idade , Neuralgia/fisiopatologia , Estudos Prospectivos , Reflexo/efeitos dos fármacos , Sensação/efeitos dos fármacos , Adesivo Transdérmico/efeitos adversos , Resultado do TratamentoRESUMO
The capsaicin 8 % patch (QUTENZA®) is an adhesive patch containing a high concentration (8 % w/w) of synthetic capsaicin, a selective agonist of transient receptor potential vanilloid 1 channel. It is approved for treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for pain in the EU; it is only approved to treat postherpetic neuralgia (PHN) in the USA. In patients with painful diabetic peripheral neuropathy (PDPN), a single 30-min application of the capsaicin 8 % patch significantly improved pain relief and sleep quality compared with placebo in a 12-week double-blind trial. In a 52-week, randomized trial, up to seven consecutive 30-min treatments with the capsaicin 8 % patch (≤7 treatments each at least 8 weeks apart) plus standard of care therapy was associated with sustained pain relief and no negative neurological safety consequences compared with standard of care. In two randomized trials, a single 60-min application of the capsaicin 8 % patch reduced pain scores significantly more than a low-concentration (0.04 %) capsaicin control patch in patients with PHN. Capsaicin 8 % patch treatment was noninferior to pregabalin (optimized dosage) in a randomized trial in patients with nondiabetic peripheral neuropathic pain. Results in two trials in patients with HIV-AN were equivocal, with a significant improvement in pain intensity observed in one trial, but not in the other. The capsaicin 8 % patch was associated with expected, transient, capsaicin-related application-site adverse events such as erythema and pain.
Assuntos
Capsaicina/administração & dosagem , Capsaicina/uso terapêutico , Neuropatias Diabéticas/tratamento farmacológico , Neuralgia Pós-Herpética/tratamento farmacológico , Doenças do Sistema Nervoso Periférico/tratamento farmacológico , Adesivo Transdérmico , Capsaicina/efeitos adversos , Capsaicina/farmacocinética , Humanos , Manejo da Dor , Pregabalina/uso terapêutico , Fármacos do Sistema Sensorial/efeitos adversos , Fármacos do Sistema Sensorial/farmacocinética , Fármacos do Sistema Sensorial/farmacologia , Fármacos do Sistema Sensorial/uso terapêutico , Adesivo Transdérmico/efeitos adversosRESUMO
Fentanyl is a potent synthetic opioid. Abuse of fentanyl patches is rarely occurring, but has been described. In this case a patient had been drinking hot tea mixed with two fentanyl patches. He was found unconscious, with convulsions and respiratory insufficiency. He was intubated and he responded to naloxone treatment, which was repeated several times during the observation. When fentanyl patches are abused this way large quantities of fentanyl are absorbed, giving severe and prolonged effect - exceeding the antidote. The patient must be observed for several hours in an intensive care unit.
Assuntos
Analgésicos Opioides/intoxicação , Fentanila/intoxicação , Adulto , Analgésicos Opioides/administração & dosagem , Fentanila/administração & dosagem , Humanos , Masculino , Intoxicação/tratamento farmacológico , Insuficiência Respiratória/induzido quimicamente , Convulsões/induzido quimicamente , Chá/efeitos adversos , Adesivo Transdérmico/efeitos adversosRESUMO
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most used drugs in musculoskeletal disorders, but their systemic adverse effects limit their therapeutic benefit in local inflammation. On the other hand, topical preparations of capsaicinoids are widely used for musculoskeletal disorders as a complementary therapy. In this study, the effects of both topical capsaicinoids-containing patch and local subcutaneous capsaicin application on the anti-inflammatory action of NSAID were examined. Carrageenan-induced paw oedema of rats was used as the inflammation model. The volume and weight of the paw oedema and plasma extravasation in the paw were determined after carrageenan injection. The systemic application of diclofenac (3 mg/kg), which is an NSAID, significantly decreased the volume and weight of the paw oedema. Topical capsaicinoids-containing patch application or local capsaicin injection (2, 10, 20 µg/paw) alone did not cause any effect on oedema volume and weight. However, the combination of diclofenac with topical capsaicinoids-containing patch significantly increased the effectiveness of diclofenac on inflammation. Evans blue content of the paws that represents plasma extravasation was decreased by capsaicinoids-containing patch with and without diclofenac and diclofenac combination with the lowest dose of capsaicin injection. The results of this study indicate that topical application of capsaicinoids-containing patch enhances the anti-inflammatory effect of diclofenac and its beneficial effect may not purely relate to its capsaicin content. In the treatment of local inflammatory disorders, the combination of NSAID with topical capsaicinoids-containing patch could increase the anti-inflammatory efficiency of drug without systemic side effects.
Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Capsaicina/análogos & derivados , Diclofenaco/uso terapêutico , Modelos Animais de Doenças , Edema/prevenção & controle , Extratos Vegetais/uso terapêutico , Fármacos do Sistema Sensorial/uso terapêutico , Animais , Anti-Inflamatórios não Esteroides/administração & dosagem , Anti-Inflamatórios não Esteroides/efeitos adversos , Anti-Inflamatórios não Esteroides/agonistas , Capsaicina/administração & dosagem , Capsaicina/efeitos adversos , Capsaicina/uso terapêutico , Capsicum/química , Carragenina , Diclofenaco/administração & dosagem , Diclofenaco/efeitos adversos , Diclofenaco/agonistas , Relação Dose-Resposta a Droga , Edema/imunologia , Feminino , Frutas/química , Interações Ervas-Drogas , Injeções Intramusculares , Injeções Subcutâneas , Extratos Vegetais/administração & dosagem , Extratos Vegetais/efeitos adversos , Extratos Vegetais/química , Distribuição Aleatória , Ratos , Ratos Wistar , Fármacos do Sistema Sensorial/administração & dosagem , Fármacos do Sistema Sensorial/efeitos adversos , Fármacos do Sistema Sensorial/química , Adesivo Transdérmico/efeitos adversosRESUMO
The skin irritating, sensitizing, and acute dermal toxicity potential of a novel combinational prophylactic transdermal patch, mainly composed of eserine and pralidoxime chloride as active pharmaceutical ingredients, against (±) anatoxin-a poisoning were investigated in rabbits, guinea pigs, and rats in compliance with the Organisation for Economic Cooperation and Development guidelines. In primary skin irritation test, rabbits were dermally attached with the therapeutically active transdermal patch or with a placebo patch for 72 hours. The transdermal patches did not induce any adverse reactions such as erythema and edema on intact skin sites. The active patch was classified as a practically nonirritating material based on the score in the primary irritation index. In the Buehler test, guinea pigs were sensitized by the active or placebo transdermal patches attached for 24 hours. The patches did not induce any sensitization reactions in contrast to a severe sensitization reaction that occurred in the positive control. Therefore, the active patch and placebo patch were both graded as weak in sensitization score and rate. Acute dermal toxicity test in rats did not produce any overt signs of toxicity following a 14-day treatment period. Taken together, these findings suggest that the transdermal patch does not cause skin irritation, skin sensitization, or dermal toxic effects following dermal application.
Assuntos
Pele/efeitos dos fármacos , Adesivo Transdérmico/efeitos adversos , Tropanos/intoxicação , Administração Cutânea , Animais , Toxinas de Cianobactérias , Avaliação Pré-Clínica de Medicamentos , Feminino , Guias como Assunto , Cobaias , Masculino , Fisostigmina/farmacologia , Compostos de Pralidoxima/farmacologia , Coelhos , Ratos , Pele/patologia , Testes Cutâneos , Testes de Toxicidade AgudaRESUMO
The aim of the study was to formulate and evaluate topically applied ketoprofen gels and patches and to see the effect of naturally occurring almond oil as penetration enhancer on the penetration of ketoprofen through artificial membrane/rabbit skin. Prior to ketoprofen gel and patch formulation, the particle size and particle size determination of ketoprofen was analyzed by Particle size analyzer (Horiba LA300). Ketoprofen gels and patches were formulated and almond oil was added in several concentrations i.e. 0.5%, 1%, 1.5%, 2%, 2.5% and 3%. The formulated gels were evaluated by several parameters like pH, spreadibility, consistency, homogeneity, skin irritation and drug content determination. In vitro drug permeation studies from transdermal gels and patches were carried out across artificial membrane and rabbit skin by using Franz Cell Apparatus (PermeGear, USA). Kinetics model was employed to the release patterns of ketoprofen from gel and patches in order to investigate the drug transport mechanism. The cumulative amount of drug penetrated from different formulations was statistically evaluated by using One-way analysis of variance (ANOVA). Stability study was performed for various batches of ketoprofen transdermal gel. Almond oil as penetration enhancer in various concentrations significantly enhances the penetration of drug from transdermal gels and patch across synthetic membrane/rabbit skin but was most significant when used in 3% concentration.